Related references
Note: Only part of the references are listed.Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas
Audrey Bouillez et al.
CANCER RESEARCH (2016)
DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells
H. Rajabi et al.
ONCOGENE (2016)
Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells
Masanori Hasegawa et al.
ONCOTARGET (2016)
MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia
Ashujit Tagde et al.
ONCOTARGET (2016)
Integrated analysis of gene expression and DNA methylation changes induced by hepatocyte growth factor in human hepatocytes
Cheng-Rong Xie et al.
MOLECULAR MEDICINE REPORTS (2015)
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma
Ulrik Lassen et al.
NEURO-ONCOLOGY (2015)
MUC1-C activates the TAK1 inflammatory pathway in colon cancer
H. Takahashi et al.
ONCOGENE (2015)
Reassessment of scoring systems and prognostic factors for metastatic spinal cord compression
Emeline Tabouret et al.
SPINE JOURNAL (2015)
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway
Emeline Tabouret et al.
ONCOTARGET (2015)
Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas
Kristin Schneider et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma
Poonam Sonawane et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations
Dominique Figarella-Branger et al.
NEURO-ONCOLOGY (2014)
Targeting MET for glioma therapy
Ahmed J. Awad et al.
NEUROSURGICAL FOCUS (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
Arman Jahangiri et al.
CLINICAL CANCER RESEARCH (2013)
Targeted Methylation and Gene Silencing of VEGF-A in Human Cells by Using a Designed Dnmt3a-Dnmt3L Single-Chain Fusion Protein with Increased DNA Methylation Activity
Abu Nasar Siddique et al.
JOURNAL OF MOLECULAR BIOLOGY (2013)
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
John F. de Groot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2011)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR
Valeria Valente et al.
BMC MOLECULAR BIOLOGY (2009)
Prognostic Significance of c-Met Expression in Glioblastomas
Doo-Sik Kong et al.
CANCER (2009)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2009)
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Christian Fischer et al.
NATURE REVIEWS CANCER (2008)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
The RIN: an RNA integrity number for assigning integrity values to RNA measurements
A Schroeder et al.
BMC MOLECULAR BIOLOGY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation
P Mezquita et al.
ONCOGENE (2005)
c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression
TA Baudino et al.
GENES & DEVELOPMENT (2002)
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
P Carmeliet et al.
NATURE MEDICINE (2001)
A new mathematical model for relative quantification in real-time RT-PCR
MW Pfaffl
NUCLEIC ACIDS RESEARCH (2001)
Share Paper
